| Abstract P031 – Table 1. Characteristics and treatment patterns of ART‐experienced doravirine users with a baseline viral load, N = 790. | |||
|---|---|---|---|
| ART‐experienced, VL <50 (N = 435) | ART‐experienced, VL ≥50 to <200 (N = 122) | ART‐experienced, VL ≥200 (N = 233) | |
| Median age (IQR) | 54 (43 to 61) | 54 (45 to 59) | 49 (39 to 56) |
| Male sex, n (%) | 329 (76) | 99 (81) | 163 (70) |
| Black race, n (%) | 145 (33) | 45 (37) | 145 (62) |
| History of AIDS‐defining events, n (%) | 168 (39) | 49 (40) | 117 (50) |
| Comorbidities, n (%) | 392 (90) | 115 (94) | 208 (89) |
| Median VACS indexa (IQR) | 22 (12 to 34) | 18 (12 to 28) | 35 (19 to 52) |
| Median calendar year of ART initiation (IQR) | 2014 (2010 to 2017) | 2016 (2012 to 2018) | 2015 (2012 to 2018) |
| NNRTI included in prior regimen | 60 (15) | ≤5b | 7 (3) |
| DOR/3TC/TDF single tablet formulation, n (%) | 112 (26) | 11 (9) | 38 (16) |
| Anchor agent | |||
| DOR only | 139 (32) | 12 (10) | 39 (17) |
| DOR + other anchor agent(s)c | 296 (68) | 110 (90) | 194 (83) |
3TC, lamivudine; DOR, doravirine; IQR, interquartile range; TDF, tenofovir disoproxil fumarate; VACS, Veterans Aging Cohort Study; VL, viral load.
aVeterans Aging Cohort Study (VACS) index: 5‐year mortality index, scored by summing pre‐assigned points for age, CD4 cell count, HIV‐1 RNA, hemoglobin, platelets, aspartate and alanine transaminase, creatinine, and viral hepatitis C infection. A higher score is associated with a higher risk of 5‐year all‐cause mortality;
bHealth Insurance Portability and Accountability Act (HIPAA) requires the masking of cells with one to five individuals;
cintegrase strand transfer inhibitor (INSTI), protease inhibitor (PI), non‐nucleoside reverse transcriptase inhibitor (NNRTI), attachment inhibitor, fusion inhibitor.